Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar
about
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryAntiplatelet Therapy in Hemodialysis Patients Undergoing Percutaneous Coronary InterventionsCoronary artery revascularization in patients with diabetes mellitusPsychosocial Factors in Diabetes and Cardiovascular RiskState-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus.Clopidogrel: the data, the experience, and the controversies.Effectiveness of percutaneous coronary intervention with drug-eluting stents compared with bypass surgery in diabetics with multivessel coronary disease: comprehensive systematic review and meta-analysis of randomized clinical dataEarly clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry.Oral antiplatelet therapy for acute and chronic management of NSTE ACS: residual ischemic risk and opportunities for improvement.Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data.Differences in thrombus structure and kinetics in patients with type 2 diabetes mellitus after non ST elevation acute coronary syndrome.Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus.Mortality after percutaneous coronary revascularization: Prior cardiovascular risk factor control and improved outcomes in patients with diabetes mellitus.Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: impact of clinical status and procedural characteristics.Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor.Implementing genotype-guided antithrombotic therapy.Current concepts on antiplatelet therapy: focus on the novel thienopyridine and non-thienopyridine agents.Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial.A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.Revascularization for coronary artery disease in diabetes mellitus: angioplasty, stents and coronary artery bypass grafting.Clinician's guide to the updated ABCs of cardiovascular disease prevention.Antithrombotic therapy for long-term secondary prevention of acute coronary syndrome in high-risk patients.Aspirin for primary prevention of cardiovascular disease in diabetes mellitusOral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview.Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspectiveVorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial.Percutaneous treatment in acute coronary syndromes.Current antiplatelet treatment strategy in patients with diabetes mellitus.Recognition of incident diabetes mellitus during an acute myocardial infarctionDiabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational studyThe Influence of Haemoglobin A1c Levels on Platelet Aggregation and Platelet Turnover in Patients with Coronary Artery Disease Treated with AspirinIncreased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapyOral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options.Long-Term Outcomes in Patients With Diabetes Mellitus Related to Prolonging Clopidogrel More Than 12 Months After Coronary Stenting.Increased Benefit With Vorapaxar Use in Patients With a History of Myocardial Infarction and Diabetes Mellitus: What the Data Show Us.Shorter- versus Longer-duration Dual Antiplatelet Therapy in Patients with Diabetes Mellitus Undergoing Drug-eluting Stents Implantation: A Meta-analysis of Randomized Controlled Trials.Thrombosis - Besieged but Poorly Understood.Coronary artery disease and diabetes mellitus.Coronary intervention in diabetes: is it different.
P2860
Q22241786-617C3B89-5675-4AA8-9AD4-6A9499D27545Q26777116-4E64DB31-7A94-44B3-98E4-356FD9136232Q26824002-CA31D3C0-24EC-45F9-A486-EB44AF33B76FQ28070388-ED3CB37A-26F5-4885-8AEC-CB885DF1F443Q30373414-78AC91FE-F39C-46A7-8D2D-E73035D9BCA2Q30573045-F38006A5-087B-41C9-9029-761BE119FFD9Q30660247-59A5BF2D-E71A-4E63-82F7-DD282A7D0C21Q30800602-CFEFFB2D-9F9C-4B33-A5EC-50D61D52866BQ33554381-77A7624B-F00B-4613-AC22-4D7D17E944B5Q33584173-01DA8A89-E2CB-43E3-BC50-76C98EF43371Q33602359-27E980C0-E67F-4690-8379-412AA6FE3FC0Q33685876-219C666B-1FAD-4795-9F99-3B8C74A2C3F5Q33706621-378E0C62-220F-40DB-B456-C9D93AEDDFE1Q33834055-8F485814-3C51-4BCC-BC13-BB13E28F201EQ33876187-4785D032-B513-4677-86D2-B6CC2A6EE7EBQ33902628-2F90BB03-7813-4BF4-B156-2197FAB225F8Q33990428-D8DD9AD9-CD88-47C6-AE3F-0CC268140CC0Q34382431-21652533-63C4-4527-ACBB-B40E96E64EDAQ34404150-0BDD8B00-E25B-4BE4-B765-6B9EACC9D147Q34751965-CFCF9565-DE8A-4B05-BD8B-9A6430C15EE9Q34793647-E1047F47-530A-4A37-87D0-73517396E565Q35070830-F9769801-D58E-4DED-BDD9-9C9BDEF5F910Q35111496-F606B679-56EF-41AD-9655-CAB4ACAF4355Q35132896-8B907A28-8EE8-48F5-961B-3066934A964BQ35141772-31A9D407-21F9-493A-ABF4-C7F617B768C1Q35174193-5BCD7B4F-477F-4ECC-BC92-7A47026405E7Q35195203-01D67320-7FCD-440C-B0B5-494ACD2E13E5Q35510430-85D4C260-C4CE-4631-A6E6-804E1C53D626Q35544048-77351AE6-FADA-4194-9CE6-C174D552E803Q35629691-A860DF1B-7BD0-41CA-B55D-285F19FF0659Q35677083-71E53675-F745-4448-82A4-EA87C737F34CQ35684231-68BA37BA-4690-443B-90C0-451EC36FD06CQ35755253-426BB2E3-45A5-42D0-8A0F-6BC6C63924D0Q35797491-A728459D-CFD5-43F1-9E44-210F26462982Q36081846-C504D560-28DE-4959-ABC6-4425BEE18158Q36094523-34B34F4A-6B12-45D3-9F27-A62030AA7749Q36207603-16C64129-E7AA-493D-840D-187D2E6CB4EEQ36344748-C13724BF-03EF-4C8B-B1B5-518F73FC0E43Q36355228-E48EEFC1-7C53-4F1A-8B60-DC50A172BAA7Q36801055-47EF7AE5-6DF7-4D6E-B5C4-452AD803DDEF
P2860
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Greater clinical benefit of mo ...... asugrel-Thrombolysis in Myocar
@en
Greater clinical benefit of mo ...... asugrel-Thrombolysis in Myocar
@nl
type
label
Greater clinical benefit of mo ...... asugrel-Thrombolysis in Myocar
@en
Greater clinical benefit of mo ...... asugrel-Thrombolysis in Myocar
@nl
prefLabel
Greater clinical benefit of mo ...... asugrel-Thrombolysis in Myocar
@en
Greater clinical benefit of mo ...... asugrel-Thrombolysis in Myocar
@nl
P2093
P1433
P1476
Greater clinical benefit of mo ...... asugrel-Thrombolysis in Myocar
@en
P2093
Anthony J Dalby
Carolyn H McCabe
Dominick J Angiolillo
Drew A Purdy
Freek W A Verheugt
Ramon Corbalan
Sabina A Murphy
Shaun G Goodman
Simha Meisel
Stephen D Wiviott
P304
P356
10.1161/CIRCULATIONAHA.108.791061
P407
P577
2008-08-31T00:00:00Z